Новый класс антидиабетических препаратов - ингибиторы натрий-глюкозных котранспортеров
- Авторы: Ушкалова Е.А1
-
Учреждения:
- РУДН
- Выпуск: № 16 (2013)
- Страницы: 33-36
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/282410
- ID: 282410
Цитировать
Полный текст
Открытый доступ
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
Рассматриваются свойства канаглифлозина и дапаглифлозина - первых представителей нового класса сахароснижающих препаратов: пероральных ингибиторов натрий-глюкозного котранспортера 2-го типа (SGLT2), недавно разрешенных к применению в США и Европе соответственно. Ингибиторы SGLT2 снижают концентрацию глюкозы в крови за счет не зависимого от инсулина снижения реабсорбции глюкозы в проксимальных почечных канальцах, т. е. стимуляции ее выведения с мочой. Эффективность канаглифлозина и дапаглифлозина в лечении больных сахарным диабетом 2 типа продемонстрирована в контролируемых клинических испытаниях. Подчеркивается, что их место в терапии диабета должны определить результаты будущих клинических и фармакоэпидемиологических исследований.
Полный текст
Список литературы
- Hardman TC, Dubrey SW. Development and Potential Role of Type-2 Sodium-Glucose Transporter Inhibitors for Management of Type 2 Diabetes. Diabetes Ther 2011;2(3):133-45.
- Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-77.
- Wright EM. Renal Na+-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10-8.
- Moe OW, Wright SH, Palacin M. Renal handling of organic solutes. In: Brenner BM, ed. Brenner and Rector's The Kidney. 8th edition. Philadelphia: Saunders Elsevier, 2008:214-47.
- О-арилглюкозидные ингибиторы SGLT2 и способ их применения. Патент РФ № 2269540 (2006.02.10).
- Sabino-Silva R, Mori RC, David-Silva A, et al. The Na(+)/glucose cotransporters: from genes to therapy. Braz J Med Biol Res 2010;43(11):1019-26.
- Ehrenkranz RRL, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-8.
- Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-26.
- Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-29.
- Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51:1145-49.
- Macdonald FR, Peel JE, Jones HB, et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab 2010;12:1004-12.
- Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010;12:510-16.
- Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010;38:405-14.
- Shah NK, Deeb WE, Choksi R, Epstein BJ. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2012;32(1):80-94.
- United States Food and Drug Administration. FDA briefing document: NDA 202293 dapagliflozin tablets, 5 and 10 mg sponsor: Bristol-Myers Squibb.http://www. fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/drugs/ndocrinologicandMetabolicDrugsAdvisoryCommittee/ ucm262994.pdf
- Jones D. Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat Rev Drug Discov 2011;10(9):645-46.
- European Medicine's Agency. Summary of opinion: Forziga. http://www.ema.europa.eu/docs/ en_GB/document_library/Summary_of_opin-ion_-_Initial_authorisation/human/002322/ WC500125684.pdf
- INVOKANA™ [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2013.
- Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 1995;2013;41(2):72-84.
- Yale J-F, Bakris G, Figueroa K, et al. Canagliflozin (CANA), a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor, Improves Glycemia and is Well Tolerated in Type 2 Diabetes Mellitus (T2DM) Subjects With Moderate Renal Impairment http:// www.abstractsonline.com/Plan/ViewAbstract. aspx?sKey=b266eaf6-c060-450a-9a54-ae244aae03af&cKey=062eb968-9ab7-4c0d-baa7-7272b7db6a6d&mKey=%7b0F70410F-8DF3-49F5-A63D-3165359F5371%7d
- Babu A. Canagliflozin for the treatment of type 2 diabetes. Drugs Today (Barc) 2013; 49(6):363-76.
- Nisly SA, Kolanczyk DM, Walton AM. Canagliflozin, a new sodium-glucose (SGLT2). Однако место этих препаратов в лечении СД2 должны определить результаты будущих клинических и фармакоэпидемиологических исследований. cotransporter 2 inhibitor, in the treatment of diabetes.Am J Health Syst Pharm 2013;70(4): 311-19.
- Gross JL, Schernthaner G, Fu M, et al. Efficacy and Safety of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, Compared with Sitagliptin in Patients with Type 2 Diabetes On Metformin Plus Sulfonylurea. http://www. abstractsonline. com/Plan/ViewAbstract. aspx?sKey=b266eaf6-c060-450a-9a54-ae244aae03af&cKey=0fb4f41e-05c7-4d2e-8707-eecb5716be63&mKey=%7b0F70410F-8DF3-49F5-A63D-3165359F5371%7d
- Cefalu W, Leiter LA, Niskanen L, et al. Efficacy and Safety of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, Compared With Glimepiride in Patients with Type 2 Diabetes on Background Metformin. http://www. abstractsonline. com/Plan/ViewAbstract. aspx?sKey=b266eaf6-c060-450a-9a54-ae244aae03af&cKey=33145c27-7078-4570-9094-553cc24b9c50&mKey=%7b0F70410F-8DF3-49F5-A63D-3165359F5371%7d
- Lamos EM, Younk LM, Davis SN. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2013;9(6):763-75.
- Experts Express Mixed Thoughts on Canagliflozin Approval. Medscape Medical News. Apr 18, 2013 http://www.medscape.com/viewarticle/782712
- Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial. Am Heart J 2013;166(2): 217-23.
- FDA Approves Canagliflozin, a First-in-Class Diabetes Drug. Medscape. Mar 29, 2013.http:// www.medscape.com/viewarticle/781709
- Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012;5:313-27.
- Diamant M, Morsink LM.SGLT2 inhibitors for diabetes: turning symptoms into therapy. Lancet. 2013 Jul 11 [Epub ahead of print].
Дополнительные файлы
